Most people with rheumatoid arthritis live into their 70s and beyond, but the condition does shorten life expectancy compared to the general population. Studies consistently show that RA raises the overall risk of premature death, primarily through cardiovascular disease, respiratory complications, and infections. The good news: that gap has been narrowing for decades, and people diagnosed today have significantly better odds than those diagnosed in the 1980s or 1990s.
How RA Affects Life Expectancy
RA is not a terminal illness, but it is a systemic disease, meaning it affects more than just your joints. The chronic inflammation that drives joint damage also accelerates problems in the heart, lungs, and other organs. Over large populations, this translates to a shorter average lifespan. Older studies frequently cited a reduction of 3 to 10 years, though that range depends heavily on disease severity, when treatment started, and what era the data came from.
The mortality risk has been declining since the 1980s. A 2025 study in The Journal of Rheumatology confirmed that all-cause mortality in RA patients, while still elevated compared to the general population, has dropped over time. This tracks closely with the introduction of more effective treatments, earlier diagnosis, and better management of the cardiovascular risks that come with chronic inflammation.
What Actually Causes Earlier Death in RA
RA itself rarely appears on a death certificate as the direct cause. Instead, it accelerates other conditions. The leading underlying causes of death in RA patients are circulatory diseases (35% of deaths) and respiratory diseases (22%). Within circulatory causes, ischemic heart disease (heart attacks and related conditions) accounts for about 11.5%, followed by stroke at 5.5%.
The complications that most often accompany RA at the time of death paint a fuller picture. Pneumonia is present in nearly 39% of RA-related deaths, sepsis (overwhelming infection) in about 30%, kidney failure in 11%, interstitial lung disease in 11%, and heart failure in 9%. These numbers reflect how RA’s constant inflammation, combined with immune-suppressing treatments, creates vulnerability across multiple organ systems simultaneously.
Cardiovascular Risk Is the Biggest Factor
People with RA face roughly 1.5 times the cardiovascular risk of someone without the disease. Multiple large analyses have found that the chance of dying from a cardiovascular event is 50 to 60% higher in RA patients. This isn’t just because RA patients happen to have more traditional risk factors like high cholesterol or smoking. The inflammation itself damages blood vessels, promotes plaque buildup, and stiffens arteries in ways that go beyond what standard heart risk calculators predict.
This is one of the most actionable pieces of information for anyone living with RA. Managing blood pressure, cholesterol, weight, and physical activity matters even more for you than for the average person. Many rheumatologists now screen for cardiovascular risk as part of routine RA care.
Lung Disease and RA
Interstitial lung disease, a condition where scarring gradually stiffens the lungs and makes breathing harder, is one of the more serious complications of RA. Among patients who develop it, about 36% die within five years of diagnosis, and median survival is roughly 7.8 years. Not everyone with RA develops lung involvement, but it’s a significant driver of the mortality gap, particularly for those who test positive for certain antibodies.
Seropositive vs. Seronegative RA
Your blood test results at diagnosis carry meaningful information about long-term risk. People with seropositive RA, meaning they test positive for rheumatoid factor or anti-CCP antibodies, have a significantly higher risk of death than those with seronegative RA. The difference is especially stark for respiratory causes: seropositive patients face more than double the risk of dying from lung-related complications, while seronegative patients show no increased respiratory mortality at all compared to the general population.
This doesn’t mean seronegative RA is harmless. It still causes joint damage and reduces quality of life. But in terms of life expectancy specifically, seronegative patients appear to face a much smaller penalty.
How Modern Treatment Changes the Outlook
The single most important development for RA survival has been the availability of biologic medications and early, aggressive treatment strategies. A population-based study comparing RA patients who used biologics to matched controls who did not found that biologic users had roughly 75% lower risk of death. That’s a dramatic difference, and it held up across multiple ways of analyzing the data.
Starting treatment early matters too. Research confirms that beginning medication sooner after symptoms appear leads to better disease control, greater preservation of joint function, and a higher chance of achieving sustained remission. While there doesn’t appear to be a hard cutoff or “closing window” after which treatment stops working, the benefits decline gradually with each month of delay. People who start combination therapy early do better than those who begin with a single, slower-acting medication.
The practical takeaway: the earlier RA is controlled, the less cumulative inflammation your body endures, and the less damage it does to your heart, lungs, and other organs over a lifetime.
What Determines Your Individual Outlook
Population averages don’t tell you much about any single person’s life. Several factors shift your individual risk substantially:
- Disease activity: Persistently active, poorly controlled RA carries the highest risk. People who achieve low disease activity or remission approach normal life expectancy.
- Serostatus: Seropositive RA carries higher mortality risk, particularly from respiratory causes.
- Cardiovascular health: Because heart disease is the leading killer in RA, your baseline cardiovascular fitness and risk factors matter enormously.
- Smoking: Smoking worsens RA disease activity, accelerates lung disease, and compounds cardiovascular risk. It’s one of the most modifiable factors.
- Treatment adherence: Consistent use of disease-modifying medications dramatically improves survival, as the biologic data shows.
- Age at diagnosis: Younger patients have more years for treatment to protect them, but also more years of cumulative disease exposure if control is poor.
RA diagnosed and well-managed in 2025 is a fundamentally different disease than RA diagnosed in 1990. The treatments are better, the monitoring is more precise, and the understanding of cardiovascular and lung risks means those complications are caught and addressed earlier. For someone whose RA is diagnosed promptly and responds well to treatment, the impact on lifespan may be modest to negligible. For someone with severe, treatment-resistant disease and existing heart or lung problems, the stakes are higher, but even then, options exist that simply weren’t available a generation ago.